[1] |
KLEEFF J, WHITCOMB DC, SHIMOSEGAWA T, et al. Chronic pancreatitis[J]. Nat Rev Dis Primers, 2017, 3: 17060. DOI: 10.1038/nrdp.2017.60.
|
[2] |
ENRIQUE DOMINGUEZ-MUÑOZ J. Diagnosis and treatment of pancreatic exocrine insufficiency[J]. Curr Opin Gastroenterol, 2018, 34( 5): 349- 354. DOI: 10.1097/MOG.0000000000000459.
|
[3] |
de la IGLESIA-GARCIA D, VALLEJO-SENRA N, IGLESIAS-GARCIA J, et al. Increased risk of mortality associated with pancreatic exocrine insufficiency in patients with chronic pancreatitis[J]. J Clin Gastroenterol, 2018, 52( 8): e63- e72. DOI: 10.1097/MCG.0000000000000917.
|
[4] |
LAI YM, WU D, YANG H, et al. Epidemiology and clinical characteristics of type 1 autoimmune pancreatitis[J]. Basic Clin Med, 2017, 37( 11): 1607- 1610. DOI: 10.16352/j.issn.1001-6325.2017.11.019.
赖雅敏, 吴东, 杨红, 等. 1型自身免疫性胰腺炎的流行病学及临床特点[J]. 基础医学与临床, 2017, 37( 11): 1607- 1610. DOI: 10.16352/j.issn.1001-6325.2017.11.019.
|
[5] |
KAMISAWA T, CHARI ST, GIDAY SA, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: An international multicenter survey[J]. Pancreas, 2011, 40( 6): 809- 814. DOI: 10.1097/MPA.0b013e3182258a15.
|
[6] |
MAIRE F, LE BALEUR Y, REBOURS V, et al. Outcome of patients with type 1 or 2 autoimmune pancreatitis[J]. Am J Gastroenterol, 2011, 106( 1): 151- 156. DOI: 10.1038/ajg.2010.314.
|
[7] |
HUGGETT MT, CULVER EL, KUMAR M, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort[J]. Am J Gastroenterol, 2014, 109( 10): 1675- 1683. DOI: 10.1038/ajg.2014.223.
|
[8] |
FRULLONI L, SCATTOLINI C, KATSOTOURCHI AM, et al. Exocrine and endocrine pancreatic function in 21 patients suffering from autoimmune pancreatitis before and after steroid treatment[J]. Pancreatology, 2010, 10( 2-3): 129- 133. DOI: 10.1159/000265945.
|
[9] |
BUIJS J, CAHEN DL, van HEERDE MJ, et al. The long-term impact of autoimmune pancreatitis on pancreatic function, quality of life, and life expectancy[J]. Pancreas, 2015, 44( 7): 1065- 1071. DOI: 10.1097/MPA.0000000000000451.
|
[10] |
LANZILLOTTA M, TACELLI M, FALCONI M, et al. Incidence of endocrine and exocrine insufficiency in patients with autoimmune pancreatitis at diagnosis and after treatment: A systematic review and meta-analysis[J]. Eur J Intern Med, 2022, 100: 83- 93. DOI: 10.1016/j.ejim.2022.03.014.
|
[11] |
LÖHR JM, FAISSNER R, KOCZAN D, et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: Gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process[J]. Am J Gastroenterol, 2010, 105( 9): 2060- 2071. DOI: 10.1038/ajg.2010.141.
|
[12] |
ITO T, KAWABE K, ARITA Y, et al. Evaluation of pancreatic endocrine and exocrine function in patients with autoimmune pancreatitis[J]. Pancreas, 2007, 34( 2): 254- 259. DOI: 10.1097/01.mpa.0000250127.18908.38.
|
[13] |
NISTA EC, de LUCIA SS, MANILLA V, et al. Autoimmune pancreatitis: From pathogenesis to treatment[J]. Int J Mol Sci, 2022, 23( 20): 12667. DOI: 10.3390/ijms232012667.
|
[14] |
DETLEFSEN S, SIPOS B, ZHAO JB, et al. Autoimmune pancreatitis: Expression and cellular source of profibrotic cytokines and their receptors[J]. Am J Surg Pathol, 2008, 32( 7): 986- 995. DOI: 10.1097/PAS.0b013e31815d2583.
|
[15] |
FRULLONI L, LUNARDI C, SIMONE R, et al. Identification of a novel antibody associated with autoimmune pancreatitis[J]. N Engl J Med, 2009, 361( 22): 2135- 2142. DOI: 10.1056/NEJMoa0903068.
|
[16] |
SHCHEYNIKOV N, KIM KH, KIM KM, et al. Dynamic control of cystic fibrosis transmembrane conductance regulator Cl(-)/HCO3(-) selectivity by external Cl(-)[J]. J Biol Chem, 2004, 279( 21): 21857- 21865. DOI: 10.1074/jbc.M313323200.
|
[17] |
ISHIGURO H, STEWARD MC, NARUSE S, et al. CFTR functions as a bicarbonate channel in pancreatic duct cells[J]. J Gen Physiol, 2009, 133( 3): 315- 326. DOI: 10.1085/jgp.200810122.
|
[18] |
KO SBH, MIZUNO N, YATABE Y, et al. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis[J]. Gastroenterology, 2010, 138( 5): 1988- 1996. DOI: 10.1053/j.gastro.2010.01.001.
|
[19] |
de PRETIS N, MARTINELLI L, PALMERI E, et al. The effect of steroid therapy on pancreatic exocrine function in autoimmune pancreatitis[J]. Pancreatology, 2024, 24( 4): 538- 544. DOI: 10.1016/j.pan.2024.04.006.
|
[20] |
ZHANG BB, JIN EH. MRCP features of pancreatic duct lesions in autoimmune pancreatitis[J]. Chin J Med Imag Technol, 2017, 33( 2): 232- 236. DOI: 10.13929/j.1003-3289.201608151.
张斌斌, 靳二虎. 自身免疫性胰腺炎胰管病变的MRCP特征[J]. 中国医学影像技术, 2017, 33( 2): 232- 236. DOI: 10.13929/j.1003-3289.201608151.
|
[21] |
ZUO L, YANG DJ, LU HM. Clinical application of pancreatic exocrine function tests[J]. J Clin Hepatol, 2022, 38( 4): 956- 960. DOI: 10.3969/j.issn.1001-5256.2022.04.044.
左林, 杨都江, 陆慧敏. 胰腺外分泌功能检测方法的临床应用[J]. 临床肝胆病杂志, 2022, 38( 4): 956- 960. DOI: 10.3969/j.issn.1001-5256.2022.04.044.
|
[22] |
LIN JH, HU LH, LIAO Z, et al. Diagnosis and treatment status and progress of pancreatic exocrine insufficiency in chronic pancreatitis[J]. Chin J Pancreatol, 2015, 15( 6): 420- 422. DOI: 10.3760/cma.j.issn.1674-1935.2015.06.018.
林金欢, 胡良皞, 廖专, 等. 慢性胰腺炎胰腺外分泌功能不全的诊治现状与进展[J]. 中华胰腺病杂志, 2015, 15( 6): 420- 422. DOI: 10.3760/cma.j.issn.1674-1935.2015.06.018.
|
[23] |
CHAMOKOVA B, BASTATI N, POETTER-LANG S, et al. The clinical value of secretin-enhanced MRCP in the functional and morphological assessment of pancreatic diseases[J]. Br J Radiol, 2018, 91( 1084): 20170677. DOI: 10.1259/bjr.20170677.
|
[24] |
MERKLE EM, BAILLIE J. Exocrine pancreatic function: Evaluation with MR imaging before and after secretin stimulation[J]. Am J Gastroenterol, 2006, 101( 1): 137- 138. DOI: 10.1111/j.1572-0241.2006.00400.x.
|
[25] |
OCHI K, MIZUSHIMA T, HARADA H, et al. Chronic pancreatitis: Functional testing[J]. Pancreas, 1998, 16( 3): 343- 348. DOI: 10.1097/00006676-199804000-00022.
|
[26] |
LINDKVIST B. Diagnosis and treatment of pancreatic exocrine insufficiency[J]. World J Gastroenterol, 2013, 19( 42): 7258- 7266. DOI: 10.3748/wjg.v19.i42.7258.
|
[27] |
WHITCOMB DC, BUCHNER AM, FORSMARK CE. AGA clinical practice update on the epidemiology, evaluation, and management of exocrine pancreatic insufficiency: Expert review[J]. Gastroenterology, 2023, 165( 5): 1292- 1301. DOI: 10.1053/j.gastro.2023.07.007.
|
[28] |
POWELL-BRETT S, HALL L, EDWARDS M, et al. A systematic review and meta-analysis of the accuracy and methodology of the 13C mixed triglyceride breath test for the evaluation of pancreatic function[J]. Pancreatology, 2023, 23( 3): 283- 293. DOI: 10.1016/j.pan.2023.02.004.
|
[29] |
ENRIQUE DOMÍNGUEZ-MUÑOZ J, NIETO L, VILARIÑO M, et al. Development and diagnostic accuracy of a breath test for pancreatic exocrine insufficiency in chronic pancreatitis[J]. Pancreas, 2016, 45( 2): 241- 247. DOI: 10.1097/MPA.0000000000000434.
|
[30] |
SAKAI D, HIROOKA Y, KAWASHIMA H, et al. Increase in breath hydrogen concentration was correlated with the main pancreatic duct stenosis[J]. J Breath Res, 2018, 12( 3): 036004. DOI: 10.1088/1752-7163/aaaf77.
|
[31] |
VUJASINOVIC M, VALENTE R, DEL CHIARO M, et al. Pancreatic exocrine insufficiency in pancreatic cancer[J]. Nutrients, 2017, 9( 3): 183. DOI: 10.3390/nu9030183.
|
[32] |
UETSUKI K, KAWASHIMA H, OHNO E, et al. Measurement of fasting breath hydrogen concentration as a simple diagnostic method for pancreatic exocrine insufficiency[J]. BMC Gastroenterol, 2021, 21( 1): 211. DOI: 10.1186/s12876-021-01776-8.
|
[33] |
VUJASINOVIC M, NIKOLIC S, GORDON ACHOUR A, et al. Autoimmune pancreatitis and micronutrients[J]. Dig Liver Dis, 2023, 55( 10): 1375- 1381. DOI: 10.1016/j.dld.2023.04.009.
|
[34] |
Special Committee on Chronic Pancreatitis, Pancreatic Disease Specialized Committee, Chinese Medical Doctor Association. Standards for the diagnosis and treatment of pancreatic exocrine insufficiency(2018, Guangzhou)[J]. J Clin Hepatol, 2019, 35( 2): 294- 298. DOI: 10.3969/j.issn.1001-5256.2019.02.010.
中国医师协会胰腺病专业委员会慢性胰腺炎专委会. 胰腺外分泌功能不全诊治规范(2018, 广州)[J]. 临床肝胆病杂志, 2019, 35( 2): 294- 298. DOI: 10.3969/j.issn.1001-5256.2019.02.010.
|
[35] |
LINDKVIST B, PHILLIPS ME, ENRIQUE DOMÍNGUEZ-MUÑOZ J. Clinical, anthropometric and laboratory nutritional markers of pancreatic exocrine insufficiency: Prevalence and diagnostic use[J]. Pancreatology, 2015, 15( 6): 589- 597. DOI: 10.1016/j.pan.2015.07.001.
|
[36] |
ENRIQUE DOMÍNGUEZ-MUÑOZ J, PHILLIPS M. Nutritional therapy in chronic pancreatitis[J]. Gastroenterol Clin North Am, 2018, 47( 1): 95- 106. DOI: 10.1016/j.gtc.2017.09.004.
|
[37] |
SHIMIZU K, ITO T, IRISAWA A, et al. Evidence-based clinical practice guidelines for chronic pancreatitis 2021[J]. J Gastroenterol, 2022, 57( 10): 709- 724. DOI: 10.1007/s00535-022-01911-6.
|
[38] |
de la IGLESIA-GARCÍA D, HUANG W, SZATMARY P, et al. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: Systematic review and meta-analysis[J]. Gut, 2017, 66( 8): 1354- 1355. DOI: 10.1136/gutjnl-2016-312529.
|
[39] |
ARVANITAKIS M, OCKENGA J, BEZMAREVIC M, et al. ESPEN guideline on clinical nutrition in acute and chronic pancreatitis[J]. Clin Nutr, 2020, 39( 3): 612- 631. DOI: 10.1016/j.clnu.2020.01.004.
|
[40] |
NIKFARJAM M, WILSON JS, SMITH RC, et al. Diagnosis and management of pancreatic exocrine insufficiency[J]. Med J Aust, 2017, 207( 4): 161- 165. DOI: 10.5694/mja16.00851.
|
[41] |
DOMÍNGUEZ-MUÑOZ JE, IGLESIAS-GARCÍA J, IGLESIAS-REY M, et al. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: A randomized, three-way crossover study[J]. Aliment Pharmacol Ther, 2005, 21( 8): 993- 1000. DOI: 10.1111/j.1365-2036.2005.02390.x.
|
[42] |
de-MADARIA E, ABAD-GONZÁLEZ A, APARICIO JR, et al. The Spanish Pancreatic Club’s recommendations for the diagnosis and treatment of chronic pancreatitis: Part 2(treatment)[J]. Pancreatology, 2013, 13( 1): 18- 28. DOI: 10.1016/j.pan.2012.11.310.
|
[43] |
KAMISAWA T, OKAMOTO A, WAKABAYASHI T, et al. Appropriate steroid therapy for autoimmune pancreatitis based on long-term outcome[J]. Scand J Gastroenterol, 2008, 43( 5): 609- 613. DOI: 10.1080/00365520701731263.
|
[44] |
NISHINO T, TOKI F, OYAMA H, et al. Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy[J]. Intern Med, 2006, 45( 8): 497- 501. DOI: 10.2169/internalmedicine.45.1565.
|
[45] |
YAMAGUCHI T, NAKAMURA H, KIHARA Y, et al. Long-term overexpression of membrane type-1 matrix metalloproteinase and matrix metalloproteinase-2 in oleic acid-induced pancreatitis in rats[J]. Pancreas, 2002, 24( 4): 348- 356. DOI: 10.1097/00006676-200205000-00005.
|
[46] |
YAMAGUCHI T, KIHARA Y, TAGUCHI M, et al. Persistent destruction of the basement membrane of the pancreatic duct contributes to progressive acinar atrophy in rats with experimentally induced pancreatitis[J]. Pancreas, 2005, 31( 4): 365- 372. DOI: 10.1097/01.mpa.0000179729.61457.e5.
|
[47] |
NIKOLIC S, MAISONNEUVE P, DAHLMAN I, et al. Exocrine and endocrine insufficiency in autoimmune pancreatitis: A matter of treatment or time?[J]. J Clin Med, 2022, 11( 13): 3724. DOI: 10.3390/jcm11133724.
|
[48] |
NAGPAL SJS, SHARMA A, CHARI ST. Autoimmune pancreatitis[J]. Am J Gastroenterol, 2018, 113( 9): 1301. DOI: 10.1038/s41395-018-0146-0.
|
[49] |
HART PA, TOPAZIAN MD, WITZIG TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: The Mayo Clinic experience[J]. Gut, 2013, 62( 11): 1607- 1615. DOI: 10.1136/gutjnl-2012-302886.
|